

# Contents

**Preface** *xiii*

**A Personal Foreword** *xv*

## **Part I Introduction** *1*

<b>1</b>	<b>Polypharmacology in Drug Discovery</b>	<b>3</b>
	<i>Oscar Méndez-Lucio, J. Jesús Naveja, Hugo Vite-Caritino, Fernando D. Prieto-Martínez, and José L. Medina-Franco</i>	
1.1	Polypharmacology	3
1.2	Multitarget versus Target-Specific Drugs	5
1.2.1	“Master Key Compounds”	5
1.2.2	Safety Panels	8
1.3	Polypharmacology and Related Concepts in Drug Discovery	11
1.3.1	Drug Repurposing	11
1.3.2	Combination of Drugs	12
1.3.3	<i>In Vivo</i> Testing	12
1.4	Polypharmacology (and Polypharmacy): Case Studies	13
1.4.1	Polypharmacology in Epigenetics	13
1.4.2	Charting the Epigenetic Relevant Chemical Space	14
1.4.3	Polypharmacy for the Treatment of HIV Infections	15
1.5	Computational Strategies to Explore Polypharmacology	15
1.5.1	Chemogenomics: Intersection of Chemical and Biological Spaces	16
1.5.2	Structure–Multiple Activity Relationships	17
1.5.3	Proteochemometric Modeling	19
1.5.4	Target Fishing	19
1.5.5	Data Mining of Side Effects and Interactions for Drug Repurposing	20
1.5.6	Systems Pharmacology	21
1.5.7	Polypharmacology Fingerprints	21
1.6	Summary Conclusions	21
	Acknowledgments	22
	References	22

**2            Kinase Inhibitors    33**

*Peng Wu, Michael Givskov, and Thomas E. Nielsen*

- 2.1    Overview    33
- 2.2    Kinase Profiling    38
- 2.3    Definition and Quantification of Selectivity Levels    40
- 2.4    Selectivity of Approved Kinase Inhibitors    43
  - 2.4.1    Non-covalent Type I and Type II SMKIs    45
  - 2.4.2    Allosteric SMKIs    47
  - 2.4.3    Lipid Kinase Inhibitor    48
  - 2.4.4    Covalent Inhibitors    48
- 2.5    Conclusion and Perspective    48
- Acknowledgment    49
- References    49

**3            Repositioning of Drug – New Indications for Marketed  
              Drugs    55**

*Ren Kong and Stephen T. Wong*

- 3.1    Introduction    55
- 3.2    New Uses from Adverse Effects    57
  - 3.2.1    Dapoxetine for Premature Ejaculation    57
  - 3.2.2    Sildenafil for Erectile Dysfunction    58
- 3.3    New Uses Based on Known Mechanism of Action    58
  - 3.3.1    Duloxetine for Stress Urinary Incontinence (SUI)    58
  - 3.3.2    Thalidomide for Erythema Nodosum Leprosum (ENL) and Multiple Myeloma    59
- 3.4    New Uses from Genome, Network, and Signal Pathway Analysis    59
  - 3.4.1    Identification of Sunitinib and Dasatinib for Breast Cancer Brain Metastasis    59
- 3.5    New Uses Based on New Target Identification (Off-Target Effects)    62
  - 3.5.1    Antidepressant Drug, Amoxapine, for Alleviating Cancer Drug Toxicity of Irinotecan    62
- 3.6    Computational and Systematic Drug Repositioning    64
  - 3.6.1    Methods Based on Knowledge of Side Effects    64
  - 3.6.2    Methods Based on Transcriptomics Data (Transcriptional Profile)    65
  - 3.6.3    Methods Based on Genome-Wide Association Study (GWAS)    66
  - 3.6.4    Methods Based on Network and Pathways Analysis    66
  - 3.6.5    Methods Based on Off-Target Effects    67
- 3.7    Perspective    68
- Acknowledgment    73
- References    73

**4            Discovery Technologies for Drug Repurposing    79**

*Naiem T. Issa, Stephen W. Byers, and Sivanesan Dakshanamurthy*

- 4.1    Introduction    79
- 4.2    Biological Drug Screening Methods    79

4.2.1	Phenotypic Screening	79
4.2.1.1	Animal-Based Screening	80
4.2.1.2	Cell-Based Screening	80
4.2.2	Target-Based Screening	81
4.3	<i>In silico</i> Tools for Drug Repurposing	82
4.3.1	Docking	82
4.3.2	Chemoinformatics	83
4.3.3	Protein Binding Site	84
4.3.4	Combining Drug-Centric with Protein-Centric Approaches	86
4.3.5	Network Pharmacology	86
4.3.6	Mining of Big Data	88
4.4	Conclusion	89
	References	90

### **Part III Unselective Drugs in Drug Discovery 101**

<b>5</b>	<b>Personalized Medicine</b>	<b>103</b>
	<i>Christian Noe and Volker Baumann</i>	
5.1	Roots of Personalized Medicine	103
5.2	The Return of the Active Pharmaceutical Ingredients (APIs)	104
5.3	Systems Pharmacology	105
5.4	The Patient in the Focus of Research	107
5.5	Personalized Therapy	107
5.6	Gene Therapy	108
5.7	Regenerative Medicine	110
5.8	Individualized Medicines	110
5.9	Stratified Medicines	112
5.10	Drug Selectivity	113
5.11	Smart Innovation	114
5.12	Electronic Health	115
5.13	Doctor and Patient	115
5.14	The Competent Patient	116
5.15	Conclusion	117
	References	117
<b>6</b>	<b>Drug Discovery Strategies for the Generation of Multitarget Ligands against Neglected Tropical Diseases</b>	<b>135</b>
	<i>Annachiara Gandini, Federica Prati, Elisa Uliassi, and Maria L. Bolognesi</i>	
6.1	Introduction	135
6.2	Drug Discovery for NTDs: The Past, the Present, and the Future	136
6.3	Search for New Anti-Trypanosomatid MTDL Hits: A Phenotypic Approach	138
6.4	Search for New Anti-Trypanosomatid MTDL Hits: A Target-Based Approach	141
6.5	Search for New Anti-Trypanosomatid MTDL Hits: A Drug Targeting Approach	146

6.6	Search for New Anti-Trypanosomatid MTDL Hits: A Combined Target/Targeting Approach	149
6.7	Conclusions	151
	References	152
<b>7</b>	<b>Designing Approaches to Multitarget Drugs</b>	<b>161</b>
	<i>Luca Costantino and Daniela Barlocco</i>	
7.1	Introduction	161
7.2	Target-Based Approaches for Multitarget Drug Design	163
7.2.1	Designing Approaches for Structurally Related Targets	163
7.2.1.1	Fragment-Based Approach	163
7.2.2	Designing Approaches for Structurally Unrelated Targets	166
7.2.2.1	Crystallography/SAR	166
7.2.2.2	Molecular Docking/Pharmacophore Matching	167
7.3	Ligand-Based Approaches for Multitarget Drug Design	170
7.3.1	Designing Approaches for Structurally Related Targets	170
7.3.1.1	Fragment-Based Approach	170
7.3.1.2	Machine Learning	171
7.3.1.3	SAR around a Lead	173
7.3.1.4	Pharmacophore-Based Approach	176
7.3.2	Designing-In Approaches for Structurally Unrelated Targets	180
7.3.2.1	Fragment-Based Approach	180
7.3.2.2	Pharmacophore-Based Approach	180
7.3.2.3	SAR around a Lead	181
7.3.2.4	Mining Literature Data	183
7.4	Designing Approaches Based on Phenotypic Assays	186
7.5	Conclusions	189
	References	191
<b>8</b>	<b>The Linker Approach: Drug Conjugates</b>	<b>207</b>
	<i>Daniel Merk and Manfred Schubert-Zsilavecz</i>	
8.1	Introduction	207
8.1.1	Targeted Delivery	209
8.2	Drug Conjugates	209
8.2.1	Small Molecule Drug Conjugates	209
8.2.1.1	Chances and Challenges	209
8.2.1.2	Examples	210
8.2.2	Antibody–Drug Conjugates/Protein–Drug Conjugates	217
8.2.2.1	Chances and Challenges	218
8.2.2.2	Examples	219
8.2.3	Polymer–Drug Conjugates	223
8.2.3.1	Chances and Challenges	223
8.2.3.2	Examples	226
8.3	Linker Chemistry	229
8.3.1	Demands on a Linker or How to Link Drugs	229
8.3.2	Linker Types	231
8.4	Conclusion and Future Perspective	233
	References	236

<b>9</b>	<b>Merged Multiple Ligands</b>	<b>247</b>
	<i>Hongming Chen, Udo Bauer, and Ola Engkvist</i>	
9.1	Introduction	247
9.2	Computational Methods Utilized in Designing MMLs	248
9.2.1	Bioactivity Data Sources	248
9.2.2	Utilizing Known Polypharmacology to Identify MMLs	248
9.2.3	Applying QSAR Models to Identifying and Optimizing MMLs	249
9.2.4	MMLs Developed Based on Fragments	250
9.2.5	Utilizing Protein Crystal Structures in Identifying MMLs	250
9.3	Examples of Medicinal Chemistry Efforts of Designing MMLs in Drug Discovery Projects	251
9.3.1	MMLs in Oncology	251
9.3.2	MML Targeting for Neurodegenerative Disease	255
9.3.2.1	MMLs for the Treatment of Alzheimer's Disease	256
9.3.2.2	MML for the Treatment of Parkinson's Disease	257
9.3.3	MML for the Treatment of Depression	261
9.3.4	MMLs for the Treatment of Cardiovascular Diseases	262
9.3.5	MML for the Treatment of Diabetes and Related Metabolic Diseases	264
9.3.6	MML for the Treatment of Inflammation and Pain	267
9.4	Conclusions and Future Outlook	269
	References	269
<b>10</b>	<b>Pharmacophore Generation for Multiple Ligands</b>	<b>275</b>
	<i>Norbert Handler</i>	
10.1	Introduction	275
10.2	Ligand-Based Pharmacophore Modeling	276
10.3	Structure-Based Pharmacophore Modeling	278
10.4	Pharmacophore-Based Virtual Screening	279
10.5	Pharmacophore-Based <i>De Novo</i> Design	280
10.6	Limitations for Pharmacophore Modeling	282
10.7	Practical Strategy for Pharmacophore-Based Discovery of Multiple Ligands	283
10.8	Linked Fluoroquinolone–Flavonoid Hybrids as Potent Antibiotics against Drug-Resistant Microorganisms	285
10.9	<i>N</i> -Phenylquinazolin-4-Amine Hybrids as Dual Inhibitors of VEGFR-2 and HDAC	286
10.10	Dual Inhibitors of Phospholipase A2 and Human Leukotriene A4 Hydrolase as Anti-Inflammatory Drugs	287
10.11	Dual Antagonists of the Bradykinin B <sub>1</sub> and B <sub>2</sub> Receptors Based on a Postulated Common Pharmacophore from Existing Non-Peptide Antagonists	290
10.12	Dual-Acting Peptidomimetics with Opioid Agonist–Neurokinin-1 Antagonist Effect	292
10.13	Novel Dual-Acting Compounds Targeting the Adenosine A <sub>2A</sub> Receptor and Adenosine Transporter for Neuroprotection	292
10.14	Aminobenzimidazoles as Dual-Acting Butyrylcholinesterase Inhibitors and hCB <sub>2</sub> R Ligands to Combat Neurodegenerative Disorders	295

- 10.15 Dual Acetylcholinesterase Inhibitors–Histamine H3 Receptor Antagonists for Treating Alzheimer’s Disease 297
- 10.16 Identification of Potential Dual Agonists of FXR and TGR5 Using E-Pharmacophore-Based Virtual Screening 299
- 10.17 Arylboronic Acids as Dual-Acting FAAH and TRPV1 Ligands 301
- 10.18 Dual Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase 2 (MAP4K2) 304
- 10.19 Conclusion and Outlook 307
- References 307

## **11 Cellular Assays 313**

*Ye Fang*

- 11.1 Introduction 313
- 11.2 Cell-Based Molecular Assays 314
  - 11.2.1 Ligand Binding Assays 314
  - 11.2.2 Chemoproteomic-Based Assays 315
  - 11.2.3 Signaling Assays 317
  - 11.2.4 Automated Patch Clamping 318
  - 11.2.5 Protein–Protein Interaction Assays 319
  - 11.2.6 Protein Trafficking Assays 319
  - 11.2.7 Chemogenomic-Based Assays 320
- 11.3 Cell Phenotypic Assays 321
  - 11.3.1 Reporter Gene Assays 322
  - 11.3.2 High Content Imaging Assays 323
  - 11.3.3 Label-Free Cell Phenotypic Assays 324
- 11.4 Summary 326
- 11.5 Current and Future Perspectives 326
- References 327

## **Part IV Therapeutic Areas for Designed Multiple Ligands 335**

### **12 Developing Serotonergic Antidepressants Acting on More Than the Serotonin Transporter 337**

*Gerard J. Marek*

- 12.1 5-HT Transporter-Based Multiple Ligands for Depression 337
- 12.2 Beyond SSRIs: Strategies to Improve upon SSRI Antidepressant Activity 338
- 12.3 Roster of Serotonergic Targets for Drug Developed Outside of the Serotonin Transporter (SERT) 339
- 12.4 Previously Approved Antidepressants with Multiple Serotonergic Molecular Targets 340
- 12.5 Tested and Failed/Technically Difficult Dual-Acting Serotonergic Compounds 347
- 12.6 Technical Challenges to Developing New Chemical Entities with Multiple Mechanisms of Action 348

12.7	Clinical Experiments with SSRIs and 5-HT <sub>1A</sub> Agonists/Antagonists	350
12.8	Clinical Experiments with SSRIs and Drugs Possessing 5-HT <sub>2A</sub> Receptor Blockade	353
12.9	Non-SERT Serotonergic Targets Mired in Phase 2/3	355
12.10	Conclusions and Outlook	356
	List of Abbreviations	357
	References	357
<b>13</b>	<b>Multiple Ligands Targeting the Angiotensin System for Hypertension</b>	<b>369</b>
	<i>Agustin Casimiro-Garcia</i>	
13.1	Recent Advances in the Structural Basis for AT <sub>1</sub> Receptor Ligand Binding	370
13.2	Design of Dual AT <sub>1</sub> and Endothelin A Receptor Antagonists	372
13.3	Design of Dual AT <sub>1</sub> Receptor Antagonist/PPAR $\gamma$ Partial Agonists	377
13.4	Design of Dual AT <sub>1</sub> Receptor Blocker/NO-Releasing Agents	382
13.5	Design of Dual AT <sub>1</sub> Receptor Blocker/Antioxidant Activity Agents	384
13.6	Design of AT <sub>1</sub> Receptor Antagonists with Additional Activity in Other Pathways	387
13.7	Summary	388
	References	389
<b>14</b>	<b>Multiple Peroxisome Proliferator-Activated Receptor-Based Ligands</b>	<b>397</b>
	<i>Dmytro Kukhtar, Miquel Mulero, Raul Beltrán-Debón, Cristina Valls, Gerard Pujadas, and Santiago Garcia-Vallve</i>	
14.1	Introduction	397
14.2	Dual and Pan PPAR Agonists	404
14.3	Other Multiple Ligands that Act through PPARs	415
14.3.1	Angiotensin II Receptor Blockers/PPAR $\gamma$ Agonists	415
14.3.2	COX Inhibitors/PPAR $\gamma$ Agonists	421
14.3.3	Protein Tyrosine Phosphatase 1B Inhibitors/PPAR Agonists	423
14.3.4	11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 Inhibitors/PPAR Agonists	423
14.4	Conclusions	424
	Acknowledgments	424
	List of Abbreviations	424
	References	424
<b>15</b>	<b>Antibiotics</b>	<b>433</b>
	<i>Jean-Philippe Surivet and Philippe Panchaud</i>	
15.1	Design of Single-Pharmacophore Molecules Acting on Multiple Targets	434
15.1.1	Dual Inhibitors of Bacterial DNA Gyrase and Topoisomerase IV	434

15.1.1.1	Dual Inhibitors Targeting the Binding Site of Fluoroquinolones	435
15.1.1.2	(Non-fluoroquinolone) Dual Inhibitors of DNA Topoisomerases	439
15.1.1.3	Designed Multitarget-Directed Ligands Addressing the ATP-Binding Pocket	445
15.1.2	Multitarget Inhibitors of Peptidoglycan Biosynthesis	451
15.1.3	Multitarget Inhibitors of Type II Fatty Acid Synthases	454
15.2	Design of Hybrid Molecules: Dual Pharmacophores Acting on Multiple Targets	456
15.2.1	Cephalosporin-Based Hybrid Molecules	457
15.2.2	Fluoroquinolone–Oxazolidinone Hybrid Drugs	459
15.2.3	Fluoroquinolone–Aminouracil Hybrid Drugs	461
15.2.4	Fluoroquinolizine–Rifamycin Hybrid Drugs	462
15.2.5	Hybrid Molecules: Limitations and Perspectives	463
15.3	Emerging Antibacterial Drugs Allowing Multitarget-Directed Ligand Design	464
15.4	Conclusion	465
	References	466
<b>16</b>	<b>Multiple Ligands in Neurodegenerative Diseases</b>	<b>477</b>
	<i>Julien Lalut, Christophe Rochais, and Patrick Dallempagne</i>	
16.1	Introduction	477
16.2	Molecular Bases of ALZHEIMER'S Disease	478
16.2.1	Amyloid Plaques	478
16.2.1.1	The Origin of A $\beta$ Peptide Formation	478
16.2.1.2	Amyloid Plaque Aggregation	480
16.2.2	The Amyloid Cascade Hypothesis	480
16.2.3	Neurofibrillary Tangles	481
16.2.4	Oxidative Stress, Neuroinflammation, and Metal Toxicity	481
16.3	MTDLs Developed for the Treatment of Alzheimer's Disease	483
16.3.1	MTDLs Based on Acetylcholinesterase Inhibition	483
16.3.1.1	Multi-site AChE Inhibitors and Antioxidants	485
16.3.1.2	Multi-site AChE Inhibitors and Metal Chelators	485
16.3.1.3	Multi-site AChE and MAO Inhibitors	486
16.3.2	Multi-site AChE Inhibitors and Serotonin 5-HT <sub>4</sub> Receptor Agonist	486
16.3.2.1	Multi-site AChE and M2 Muscarinic Receptor Inhibitors	491
16.3.2.2	AChE Inhibitors with a Complex Pharmacological Profile	492
16.3.3	MTDLs Targeting Other Activities Relevant for the Treatment of AD	496
16.3.3.1	MTDLs Modulating $\gamma$ -Secretase and PPAR $\gamma$	496
16.3.3.2	MTDL BACE1 Inhibitors/Metal Chelators	497
16.3.3.3	MTDLs Inhibiting Muscarinic and $\sigma$ 1 Receptors	498
16.4	Parkinson's Disease	501
16.5	Conclusion	502
	References	503